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Research
A large body of evidence underscores the 
adverse effect of long-term exposure to ambi-
ent particulate matter (PM) air pollution on 
respiratory health (Brunekreef and Forsberg 
2005; Gotschi et al. 2008). Among adults 
in Switzerland, we have previously demon-
strated cross-sectionally that residents of 
more polluted areas have lower lung func-
tion (Ackermann-Liebrich et al. 1997). 
More recently, we presented evidence from 
the same population-based cohort [Swiss 
Cohort Study on Air Pollution and Lung and 
Heart Diseases in Adults (SAPALDIA)] that 
decreasing exposure to airborne PM attenu-
ated the average age-related decline in lung 
function. The associations were strongest for 
respiratory function tests reflecting small-
airway function, namely, FEF25–75 [forced 
expiratory flow between 25% and 75% of 
forced vital capacity (FVC)] (Downs et al. 
2007). Similar results from studies follow-
ing interventions such as building bypasses 
for congested traffic routes (Burr et al. 2004; 
Hedley et al. 2002) or banning environmen-
tal tobacco smoke (ETS) exposure (Goodman 
et al. 2007; Menzies et al. 2006) showed that 
the improvements in air quality were accom-
panied by a decrease in cardiopulmonary 
mortality and an improvement in respiratory 
symptoms and lung function. However, it 
is still unknown whether all subjects benefit 
equally from a reduction in air pollution.
Variation in genes mediating the patho-
biological effect of air pollution in the lung 
may codetermine the degree to which a person 
benefits from better air quality. Experimental 
evidence indicates that PM alters expression 
of tumor protein gene p53, cyclin-dependent 
kinase inhibitor 1A gene (p21), and the cyclin 
D1 gene (CCND1) and subsequently affects 
cell proliferation and apoptosis of lung fibro-
blasts, lymphocytes, and alveolar epithelial 
cells (Bayram et al. 2006; Dagher et al. 2006; 
Nyunoya et al. 2006; Rosas Perez et al. 2007; 
Soberanes et al. 2006). PM is furthermore 
well known to induce oxidative stress in the 
airways (Li et al. 2008). In fact, the expres-
sion of all three gene candidates, p53, p21, 
and CCND1, in bronchial epithelial cells and 
lung fibroblasts seems to be regulated in part 
by redox-dependent mechanisms (Jiao et al. 
2008; Ranjan et al. 2006; Yao et al. 2008).
The tumor suppressor p53, a nuclear tran-
scription factor, binds to response elements in 
the promoter region of many genes and plays 
a pivotal role in apoptosis. It induces up- 
regulation of the expression of many pro-
apoptotic genes and down-regulation of anti-
apoptotic genes (Oren et al. 2002). CCND1 
(cyclin D1) is known to promote cell prolif-
eration through cell cycle G1–S phase transi-
tion. The protein p21 (also known as Waf1 
or Cip1) is a direct functional counterpart 
of CCND1 and an important downstream 
effector of p53 action that negatively regulates 
cell proliferation. CCND1, p21, and p53 all 
harbor polymorphisms of hypothesized func-
tional relevance that have been extensively 
studied in the context of cancer (Choi et al. 
2008; Lu et al. 2008; Zhou et al. 2007). In 
this study, we examined whether these poly-
morphisms modified the degree to which the 
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Background: Decreasing exposure to airborne particulates was previously associated with reduced 
age-related decline in lung function. However, whether the benefit from improved air quality 
depends on genetic background is not known. Recent evidence points to the involvement of the 
genes p53 and p21 and of the cell cycle control gene cyclin D1 (CCND1) in the response of bron-
chial cells to air pollution.
oBjective: We determined in 4,326 participants of the Swiss Cohort Study on Air Pollution and 
Lung and Heart Diseases in Adults (SAPALDIA) whether four single-nucleotide polymorphisms in 
three genes [CCND1 (rs9344 [P242P], rs667515), p53 (rs1042522 [R72P]), and p21 (rs1801270 
[S31R])] modified the previously observed attenuation of the decline in the forced expiratory flow 
between 25% and 75% of the forced vital capacity (FEF25–75) associated with improved air quality.
Methods: Subjects of the prospective population-based SAPALDIA cohort were assessed in 1991 
and 2002 by spirometry, questionnaires, and biological sample collection for genotyping. We assigned 
spatially resolved concentrations of particulate matter with aerodynamic diameter ≤ 10 µm (PM10) to 
each participant’s residential history 12 months before the baseline and follow-up assessments.
results: The effect of diminishing PM10 exposure on FEF25–75 decline appeared to be modified 
by p53 R72P, CCND1 P242P, and CCND1 rs667515. For example, a 10-µg/m3 decline in aver-
age PM10 exposure over an 11-year period attenuated the average annual decline in FEF25–75 by 
21.33 mL/year (95% confidence interval, 10.57–32.08) among participants homozygous for the 
CCND1 (P242P) GG genotype, by 13.72 mL/year (5.38–22.06) among GA genotypes, and by 6.00 
mL/year (–4.54 to 16.54) among AA genotypes.
conclusions: Our results suggest that cell cycle control genes may modify the degree to which 
improved air quality may benefit respiratory function in adults.
key words: air pollution, cell cycle, cohort study, genes, respiratory function tests. Environ Health 
Perspect 117:1420–1427 (2009). doi:10.1289/ehp.0800430 available via http://dx.doi.org/  [Online 
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age-related FEF25–75 decline was attenuated 
by reduced exposure to PM with aerodynamic 
diameter ≤ 10 µm (PM10).
Materials and Methods
SAPALDIA cohort study population. The 
study design and methodology of SAPALDIA 
have been described in detail elsewhere 
(Ackermann-Liebrich et al. 2005; Martin 
et al. 1997). In 1991, health examinations 
focusing on respiratory health status were 
conducted in 9,651 adults (18–60 years of 
age) randomly selected from population regis-
tries of eight environmentally diverse areas of 
Switzerland. Ethical approval was obtained 
from the Swiss Academy of Medical Sciences 
and the Regional Ethics Committees. Written 
informed consent was obtained from all 
participants before health examination and 
biological sample collection at both surveys. 
Nonparticipation at follow-up and missing 
information on covariates led to the exclu-
sion of participants for the present study [see 
Supplemental Material, Figure 1 and Table 2 
available online (doi:10.1289/ehp.0800430.
S1 via http://dx.doi.org)]. In summary, of 
the 9,651 subjects who initially participated 
at baseline (SAPALDIA1), 1,604 had died, 
left Switzerland, or refused to participate at 
the follow-up examination (SAPALDIA2). 
Of 8,047 cohort participants remaining, 
5,732 completed the interview questionnaire 
and spirometry at both the baseline and fol-
low-up surveys. Participants were excluded 
from the analysis (n = 1,406) if they had lived 
for < 1 year at their last residential address at 
follow-up, could not be assigned home out-
door PM10 concentrations, or did not provide 
blood samples for DNA extraction or if the 
genetic analysis of their sample was unsuccess-
ful. Thus, the present study sample included 
4,326 participants with available blood sam-
ples and genotype data and complete data 
from both surveys on spirometry, smoking 
history, PM10 exposure, and residential history 
during follow-up.
Lung function assessment. Identical 
spirometer devices (model 2200, SensorMedics 
Corp., Yorba Linda, CA, USA) and protocols 
were used at baseline and follow-up examina-
tions, and their comparability was assessed 
before the follow-up study (Künzli et al. 1995, 
2005). Details of these measurements have 
been described elsewhere (Ackermann-Liebrich 
et al. 2005; Downs et al. 2005). Briefly, three 
to eight forced expiratory lung function 
maneuvers were performed by each partici-
pant to obtain a minimum of two measures 
of FEF, FVC, forced expiratory volume in the 
first second (FEV1), and FEF25–75 that were 
considered acceptable according to American 
Thoracic Society (1995) criteria. Expiratory 
flow measures were taken from the same flow-
volume curve. For each participant, the rate 
of change in lung function was defined as 
the difference in each parameter between the 
two examinations (measurement at follow-up 
minus measurement at baseline), divided by 
the participant-specific follow-up time (in 
nontruncated years).
Selection of genetic variants. We selected 
the same common, well-studied, and poten-
tially functional candidate single-nucleotide 
polymorphism (SNP) in CCND1 [proline-
to-proline substitution at amino acid 242 
(P242P), rs9344] that we evaluated in our pre-
vious research on the interaction of CCND1 
with oxidative stress in breast and colon can-
cer (Ceschi et al. 2005; Probst-Hensch et al. 
2006). We selected one additional common 
SNP in the CCND1 gene (rs667515) based on 
a pilot study involving haplotype-tagging poly-
morphisms in CCND1 and their association 
with accelerated lung function decline in a 
subsample of the SAPALDIA cohort (unpub-
lished observations). In addition, we examined 
SNPs in two other important cell cycle control 
genes that have been repeatedly assessed in 
cancer association studies and are reported 
to have a functional effect: p53 [arginine-to-
proline substitution at amino acid 72 (R72P), 
rs1042522] (Bergamaschi et al. 2006) and p21 
[serine-to-arginine substitution at amino acid 
31 (S31R), rs1801270](Lukas et al. 1997).
Genotpying. DNA was extracted from 
EDTA-buffered whole blood as previously 
described (Ackermann-Liebrich et al. 2005). 
Genotyping strategy used was fluorescent 
5´-nuclease real-time polymerase chain reac-
tion (TaqMan, Applera Europe, Rotkreuz, 
Switzerland) methodology using ABI Prism 
7900 sequence detection system (ABI, 
Rotkreuz, Switzerland). The SNP-specific 
primers and locked nucleic acid (LNA) dual-
labeled fluorogenic probes were designed by 
Sigma Proligo (Evry, France). SNP-specific 
probes and primers were as follows: rs1042522, 
5´-CTGCTCCCC[C/G]CGTGGC-3´, for-
ward 5´-ACTGAAGACCCAGGTCCA-3´, 
reverse 5´-GCCGGTGTAGGAGCT-3´; 
rs1801270, 5´-GCTGAG[C/A]CGCGAC-3´, 
forward 5´-TGCCGCCGCCTCTT-3´, 
reverse 5´-GATGCAGCCCGCCATTAG-3´; 
rs667515, 5´-AGCTCCCTTGC[G/C]
CCC-3´,  forward 5´-TGGCTTCAT­
C A G A T G A C A A C - 3 ´ ,  r e v e r s e 
5´-AACCTGGGCTTCTCCAA-3´; rs9344, 
5´-TGTGACCC[A/G]GTAAGTGA-3´, for-
ward 5´-ACGCTTCCTCTCCAGAG­3´, 
reverse 5´-CAAGGCTGCCTGG-3´. A 
10% random sample of all DNA samples 
was regenotyped, and all geno types were con-
firmed. The genotype call rate was > 99%.
Individual residential PM10 exposure 
assessment. Air pollution exposure assessment 
has been described in detail elsewhere (Downs 
et al. 2007; Liu et al. 2007). We estimated 
PM10 exposure for each participant according 
to residential history using a hybrid exposure 
model incorporating Gaussian dispersion 
(from PolluMap model, version 2.0; Liu et al. 
2007) and geoinformation based on data on 
seasonal, meteorologic, and geographic annual 
emission characteristics from various source 
categories (e.g., traffic, industrial, regional, and 
agricultural activities) (Liu et al. 2007). Hourly 
concentrations of PM10 were simulated with a 
spatial resolution of 200 × 200 m grid cells for 
1990 and 2002. Annual average PM10 expo-
sure concentrations during follow-up were esti-
mated for each residential address with the help 
of an algorithm that allowed interpolation of 
modeled values on the basis of historical trends 
in central-site measurements between 1990 
and 2002. Evaluation of dispersion model pre-
dictions using a total of 57 PM10 Swiss central-
site monitors has been described elsewhere (Liu 
et al. 2007). Based on the validated dispersion 
model, each subject was assigned an annual 
PM10 concentration every year between 1990 
and 2002. For that purpose, modeled PM10 
concentrations were averaged over the year 
to obtain annual averages for each grid cell. 
Each participant’s residential history was coded 
using the geographic information system data. 
Assignment of individual PM10 exposure was 
performed by matching address codes with 
annual concentrations derived from the grid 
cells generated by the dispersion model.
The exposure variable used for the pres-
ent study was the difference in the annual 
average PM10 exposure between 2002 and 
1991. It was calculated for each participant 
as follows: average home outdoor PM10 con-
centration in the 12 months before the base-
line examination was subtracted from the 
corresponding average concentration in the 
12 months before the follow-up examination, 
and this difference was divided by the mean 
time of follow-up (in nontruncated years). 
In our previous study (Downs et al. 2007), 
we used two exposure indexes: a) the differ-
ence in the annual average exposure between 
2002 and 1991 (the index used in the present 
study ) and b) the “interval exposure,” defined 
as the sum of the annual exposures for each 
subject for each year of follow-up between 
their examinations. Because of the high cor-
relation (R2 > 0.9) between these two expo-
sure variables, we were unable to single out 
the superior measure in our previous report. 
Both indices showed similar associations with 
change in lung function (Downs et al. 2007).
Collection of  data on covariates . 
Information on relevant covariates known or 
likely to determine lung function decline, such 
as age, height, smoking history, ETS expo-
sure, occupational exposure, and education 
level, was gathered in a computer-assisted, 
individually administered interview based on 
the European Community Respiratory Health 
Survey questionnaire (Burney et al. 1994). 
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Current and past smoking habits, exposure to 
ETS, and occupational exposure to dust and 
fumes were assessed with the same questions at 
both surveys. Participants who reported smok-
ing < 20 packs of cigarettes and using < 360 g 
of tobacco in their lifetime at both time points 
were defined as never-smokers. Cumulative 
cigarette exposure of participants was assessed 
by pack-years smoked before the first examina-
tion and pack-years smoked during follow-up. 
Participants were asked not to smoke in the 
hour before the examination, and smoking 
was validated by measuring the carbon mon-
oxide concentration in exhaled breath using an 
EC 50 Micro-Smokerlizer (Bedfont Scientific, 
Rochester, UK). Atopic status was assessed 
at baseline using skin prick tests (Phazet; 
Pharmacia, Uppsala, Sweden) for eight com-
mon inhalant allergens: dog epithelium; cat fur; 
pollen of timothy grass, Parietaria, and birch; 
the house dust mite Dermatophagoides ptero-
nyssinus; and the molds Alternaria tenuis and 
Cladosporium herbarum (Martin et al. 1997; 
Wuthrich et al. 1996). Atopy was defined by 
an adjusted mean wheal diameter ≥ 3 mm to at 
least one allergen.
Statistical analysis. We inferred CCND1 
haplotypes from unphased genotype data 
using PHASE 2.1 algorithm software [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.0800430.S1)] (Stephens et al. 2001). 
Hardy-Weinberg equilibrium was tested using 
STATA gtab command for global κ-statistic 
testing (STATA version 10; StataCorp, 
College Station, TX, USA). All four SNPs 
were in Hardy-Weinberg equilibrium. We 
obtained Lewtonin’s linkage disequilibrium 
(LD) metric D´using STATA command pwld 
for pairwise LD. Descriptive analyses of the 
lung function parameters, PM10, smoking, 
socioeconomic variables, and other relevant 
covariates have been described previously and 
in detail in different SAPALDIA cohort study 
reports (Ackermann-Liebrich et al. 2005; 
Downs et al. 2007; Imboden et al. 2007). We 
compared baseline characteristics of the cohort 
participants included in this study (n = 4,326) 
with subjects participating only at baseline as 
well as with cohort participants excluded from 
this analysis because information on genotype 
or covariate data was missing.
Results are presented as the estimated 
effect of a 10-µg/m3 decrease in the annual 
average PM10 exposure over the follow-up 
period (ΔPM10) on the average attenuation 
of the annual decline in FEF25–75.
The association between ΔPM10 and 
the average annual rate of lung function 
decline had been previously assessed using 
mixed linear model analysis, and selection of 
relevant covariates was based on this previ-
ous investigation (Downs et al. 2007): age 
at baseline (SAPALDIA1), age2, sex, height, 
parental smoking during childhood reported 
at baseline, sine and cosine function of day 
of examination to control for seasonal effects, 
level of education at baseline, change in level 
of education, Swiss nationality, self-reported 
occupational exposure to dust and occupa-
tional exposure to fumes at SAPALDIA1 
and SAPALDIA2 (yes/no), smoking status 
at follow-up (never, former, or current), 
pack-years up to SAPALDIA1, pack-years 
between SAPALDIA1 and -2, cigarettes per 
day at SAPALDIA1 and -2, atopy, body 
mass index (BMI) at SAPALDIA1, change in 
BMI, interaction between the two BMI vari-
ables, and baseline PM10 exposure. Random 
effects were included to adjust for clustering 
of residuals within area and were assumed 
to be independent between the areas and to 
have an exchangeable correlation structure. 
To estimate main effects of gene variants of 
CCND1, p21, and p53 and rate of lung func-
tion decline, we used the same mixed model 
with random area effects additionally adjusted 
for ΔPM10. To estimate modification of the 
ΔPM10 effect on average lung function decline 
by genotype, we introduced interaction terms 
between ΔPM10 and genotypes into the 
above-described covariate-adjusted mixed 
linear models independently for each SNP. 
Also, for each SNP we evaluated three differ-
ent genetic models (codominant, dominant, 
and recessive) because previous cancer asso-
ciation studies were not conclusive about the 
underlying genetic model of the SNP effects. 
The codominant model assumes that the gene 
effect depends on the number of alleles in a 
dose-dependent manner, the dominant model 
assumes that the gene effect depends on the 
presence of at least one of two high-risk alleles, 
and the recessive model assumes that the gene 
effect depends on the presence of both high-
risk alleles. The three genetic models required 
different coding of genotypes. For each SNP 
we present the genetic model with the smallest 
interaction term p-value. We obtained effect 
estimates for the association between ΔPM10 
and average annual lung function decline in 
genotype subgroups by creating genotype- 
specific PM10 exposures variables that we 
introduced into separate covariate-adjusted 
mixed linear models. Analyses were conducted 
using SAS release 9.1 (SAS Institute Inc., Cary, 
NC, USA) and STATA version 10. p-Values 
< 0.05 were interpreted as statistically signifi-
cant for main and interaction effects. p-Values 
presented as main p-values in the tables are not 
corrected for multiple testing. Nevertheless, 
Bonferroni-corrected significance level (α = 
0.05 divided by the number of tests) is indi-
cated in tables and figures as appropriate.
Results
Population characterization. Table 1 describes 
the general characteristics of the study popula-
tion (n = 4,326), including relevant predictors 
of lung function. This is a population con-
sisting mostly of Caucasians. At follow-up 
participants were more likely to be women 
and less likely to be smokers than were non-
participants. Participants tended to gain 
weight, give up smoking, and reduce expo-
sure to dust or fumes at work or to ETS [for 
details, see Supplemental Material, Table 2 
(doi:10.1289/ehp.0800430.S1)].
In 2002, 87% of the participants were liv-
ing in the same area as in 1991, and 54% had 
the same address. In general, individual home 
outdoor concentrations of PM10 declined dur-
ing the follow-up period (Table 1), as previ-
ously described in detail (Downs et al. 2007; 
Liu et al. 2007). The median decline between 
examinations for subjects included in this 
analysis was 5.8 µg/m3 (interquartile range, 
4.2–7.3 µg/m3). Mean decline was greatest 
for participants living in urban areas and low-
est in alpine areas.
Mean lung function for the cohort was 
within the range of predicted values for the 
general population and declined during the 
follow-up period (Table 1). The mean ± 
SD annual change in mid FEF25–75 during 
the 11-year follow-up period was –74.1 ± 
70.3 mL/year in men and –68.9 ± 58.9 mL/
year in women included in this analysis.
The main effects of the investigated 
genetic variants on change in lung function 
are described in more detail in Supplemental 
Material, Table 3 (doi:10.1289/ehp.0800430.
S1). Briefly, we observed no statistically signi-
ficant associations of the polymorphisms 
either with change in FEF25–75 or with FEV1 
or FVC.
Modification of the ΔPM10 effect on aver-
age decline in lung function by genotype. As 
previously reported (Downs et al. 2007), 
a 10-µg/m3 decline in average annual home 
outdoor PM10 concentration over an 11-year 
period (ΔPM10) reduced the annual rate of 
decline in FEF25–75 on average by 11.2 mL/year 
or 16%. Here we report statistically signifi cant 
modifications of this association of ΔPM10 
with FEF25–75 decline by three of the four 
genetic variants investigated: CCND1 P242P 
[p-value for interaction (pint) = 0.017], CCND1 
rs667515 (pint = 0.006), and p53 R72P (pint = 
0.016). Figure 1A and Table 2 present results 
for the association of ΔPM10 with the aver-
age annual change in FEF25–75 within geno-
type and diplotype strata for the entire study 
population; for data for never-smokers, see 
Figure 1B and Supplemental Material, Table 4 
(doi:10.1289/ehp.0800430.S1). Equivalent 
to the previously reported main effect of 
ΔPM10 (Downs et al. 2007), the genotype-
specific results we observed in the entire study 
popu lation were comparable to those in never- 
smokers. The A allele for CCND1 P242P 
reduced the attenuating effect estimate of 
ΔPM10 on FEF25–75 decline in a codominant 
p53, CCND1, and p21 variants modify PM10 effect
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manner. A 10 µg/m3 decline in PM10 over an 
11-year period was associated with an average 
attenuation of annual decline in FEF25–75 of 6.0 
mL/year [95% confidence interval (CI), –4.54 
to 16.54] in participants with an AA genotype, 
13.7 mL/year (5.38–22.06) in heterozygous 
AG participants, and 21.3 mL/year (10.57–
32.08) in participants with a GG genotype.
For the CCND1 rs667515 SNP, the bene-
ficial ΔPM10 effect was most pronounced 
in participants homozygous for the minor 
allele (CC genotype) and attenuated annual 
FEF25–75 decline in this subgroup by 28.83 mL/
year (95% CI, 15.60–42.07) compared with 
10.39 (3.24–20.47) and 11.83 (1.32–19.47) 
among GG and GC genotypes, respectively. 
This effect modification thus followed a reces-
sive genetic model.
For the p53 R72P SNP, the observed 
effect modification followed a codominant 
model. ΔPM10 was associated with an aver-
age attenuation of annual FEF25–75 decline by 
an average of 17.4 mL/year (95% CI, 8.95–
25.78) in GG genotypes (Pro/Pro) and by an 
average of 11.6 mL/year (2.65–20.61) in CG 
genotypes (Arg/Pro) but no attenuation in 
CC genotypes (Arg/Arg).
CCND1 haplotypes 2 and 3, but not 
1 and 4, were also statistically significant 
modifiers of the ΔPM10 association with 
FEF25–75 decline. In participants exhibiting 
the CCND1 haplotype 3 (CG/CG) on both 
alleles (representing the combination of the 
single SNP alleles associated with the greatest 
lung function attenuation), the effect estimate 
for attenuation of FEF25–75 decline associated 
with ΔPM10 was 30.9 mL/year (95% CI, 
17.21–44.58) compared with 11.92 (3.40–
20.44) and 10.28 (1.22–19.35) among sub-
jects with the CG haplotype in one or none 
of their alleles (Table 2).
Genotype-specific ΔPM10 effect estimates 
for the attenuation of the average annual 
decline in FEV1 and FVC are presented in 
Supplemental Material, Table 5 (doi:10.1289/
ehp.0800430.S1). For FEV1 decline, effect 
modification by genotypes was comparable to 
that seen for FEF25–75 decline. Again, effect 
modification was strongest for the CCND1 
rs667515 SNP and for CCND1 haplo-
type3 [see Supplemental Material, Table 5 
(doi:10.1289/ehp.0800430.S1)] We observed 
no modification of the ΔPM10 effect on FVC 
decline for any of the SNPs or haplotypes.
Table 1. Characteristics of the study population: SAPALDIA cohort.
IQR, interquartile range. 
aPM10 (µg/m3) in the year before SAPALDIA1 minus PM10 in the year before SAPALDIA2. bWomen, n = 2,293; men, n = 2,033. cGenotype distribution: p21 CA, n = 594; p21 AA, n = 31. dDiplo-
type distribution is labeled as follows: –/–, none of the specific haplotype present; (rs667515, rs9344)/– (e.g., GG/–), one of the specific haplotypes present; (rs667515, rs9344)/(rs667515, 
rs9344) (e.g., GG/GG), for two of the specific haplotypes present.
Characteristic Participants (n = 4,326)
Female (%) 53.0
Swiss nationality (%) 87.7
Educational level in 2002 (professional education or higher, %) 27.9
Increase in educational level between surveys (%) 17.9
Age in 1991 [mean ± SD (years)] 41.3 ± 11.2
Height [mean ± SD (cm)] 169.3 ± 8.8
BMI in 1991 [mean ± SD (kg/m2)] 23.7 ± 3.6
BMI change [mean ± SD (kg/m2)] 2.1 ± 2.2
Smoking
 Never-smokers in 1991 (%) 48.4
 Never-smokers in 2002 (%) 49.3
 Smoking quitters during follow-up (%) 8.1
 Current smokers in 1991 (%) 29.3
 Current smokers in 2002 (%) 21.9
 No. of pack-years for current smokers in 2002 
 [median (IQR)]
26.7 (14.0–42.6)
 Cigarettes per day for current smokers in 1991  
 [median (IQR)]
20 (10–25)
 Cigarettes per day for current smokers in 2002  
 [median (IQR)]
15 (7–20)
Passive smoking and occupational exposure (%)
 ETS exposure in never-smokers in 1991 13.1
 ETS exposure in never-smokers in 2002 7.7
 Father or mother smoked during childhood 56.1
 Workplace exposure to dust and fumes in 1991 30.3
 Workplace exposure to dust and fumes in 2002 13.2
 Atopy in 1991 22.3
Change in average individual home outdoor PM10 exposurea
 All areas (n = 4,326) –5.8 (–7.3 to –4.2)
 Basel area (n = 486) –8.0 (–9.1 to –6.9)
 Wald area (n = 889) –4.5 (–4.8 to –3.9)
 Davos area (n = 318) –3.0 (–3.1 to –2.8)
 Lugano area (n = 568) –12.1 (–13.5 to –10.8)
 Montana area (n = 431) –4.0 (–4.2 to –3.7)
 Payerne area (n = 595) –5.0 (–5.3 to –4.6)
 Aarau area (n = 689) –6.4 (–6.8 to –5.8)
 Geneva area (n = 350) –6.2 (–7.3 to –5.7)
Lung function in 1991 [mean ± SD (L)]b
 FVC in women 3.82 ± 0.61
 FVC in men 5.30 ± 0.82
 FEV1 in women 3.07 ± 0.55
 FEV1 in men 4.11 ± 0.72
 FEF25–75 in women 3.07 ± 1.00
 FEF25–75 in men 3.79 ± 1.29
Characteristic Participants (n = 4,326)
Annual change [mean ± SD) (mL/year)]b 
 FVC in women –20.79 ± 34.11
 FVC in men –29.17 ± 45.47
 FEV1 in women –31.88 ± 25.72
 FEV1 in men –39.77 ± 32.91
 FEF25–75 in women –68.89 ± 58.88
 FEF25–75 in men –74.11 ± 70.24
Genotype distribution
 p53 P72R, rs1042522
 GG 2,407
 CG 1,637
 CC 282
 p21 S31R, rs1801270
 CC 3,701
 CA or AAc 625
 CCND1 P242P, rs9344
 GG 1,211
 GA 2,140
 AA 975
 CCND1 –7006G>C, rs667515
 GG 1,628
 GC 2,058
 CC 640
 Diplotype distributiond
 CCND1 haplotype 1 (rs667515, rs9344)
 –/– 3,125
 GG/– 1,088
 GG/GG 113
 CCND1 haplotype 2 (rs667515, rs9344) 
 –/– 1,251
 GA/– 2,150
 GA/GA 925
 CCND1 haplotype 3 (rs667515, rs9344) 
 –/– 1,678
 CG/– 2,048
 CG/CG 600
 CCND1 haplotype 4 (rs667515, rs9344)
 –/– 4,239
 CA/– 84
 CA/CA 3
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Discussion
Understanding the pathways by which 
PM10 damages lung structures and identify-
ing susceptible subjects are important steps 
in managing the public health challenges of 
anthropogenic ambient air pollution. In this 
study, we present novel evidence that genetic 
polymorphisms in the cell fate controlling 
genes, p53, p21, and CCND1 may modify the 
degree to which adults benefit from improved 
air quality. If confirmed by independent stud-
ies, the results are of public health relevance. 
The observed difference between genotype 
subgroups with regard to ΔPM10 effects on 
average lung function decline ranged between 
11 mL/year and 21 mL/year for FEF25–75. 
This difference compares with the observed 
excess mean annual decline in FEF25–75 of 
18 mL and 14 mL per pack per day smoked 
during follow-up by, respectively, male and 
female SAPALDIA participants who smoked 
at baseline (modeled according to Downs 
et al. 2005). This difference in lung function 
decline may seem small in absolute terms 
and from an individual perspective, but even 
slight shifts in the population distribution of 
lung function can substantially increase the 
prevalence of subjects exhibiting respiratory 
function below clinical thresholds. In addi-
tion, lung function is known to be a strong 
and independent predictor of overall mortal-
ity (Künzli et al. 2000a, 2000b).
The mechanisms by which air pollutants 
induce harmful changes in bronchial tissue 
and ultimately lead to respiratory symptoms 
and clinically relevant respiratory dysfunc-
tion have been investigated. It seems well 
established that PM directly increases oxida-
tive stress (Donaldson et al. 2003), activates 
the expression of proinflammatory cyto-
kines (e.g., tumor necrosis factor α, nuclear 
factor-κβ, and interleukin-8) (Rahman et al. 
2002) and induces the homing of inflamma-
tory cells such as neutrophils, alveolar macro-
phages, and dendritic cells, thus resulting 
in inflammation of the lung (Behndig et al. 
2006; Bosson et al. 2008; Li et al. 1996,1997; 
Nightingale et al. 2000). The toxic effects of 
PM are further enhanced by bronchial tissue 
injuries and increased epithelial permeability 
(Morrison et al. 1999).
Our results are in line with more recent 
in vitro experiments with different types of 
bronchial cell lines demonstrating that PM 
induces cell proliferation arrest and apoptosis 
in exposed cells (Bayram et al. 2006; Dagher 
et al. 2006; Rosas Perez et al. 2007; Soberanes 
et al. 2006; Upadhyay et al. 2003; Zhang 
et al. 2007). Air pollutants or cigarette smoke, 
both exhibiting oxidative properties, specifi-
cally alter the expression levels of tumor sup-
pressor genes such as p53 and p21 and of the 
cell cycle control gene CCND1 in human 
and rodent in vitro bronchial cell culture 
Figure 1. Attenuation of average annual FEF25–75 decline associated with a 10-µg/m3 decrease in average 
home outdoor PM10 exposure between 1991 and 2002, by genotype status, in all study participants (A) and 
in never-smokers only (B). A positive value for FEF25–75 on the y-axes represents the average attenuation 
in lung function decline associated with an average 10-µg/m3 PM10 decrease during follow-up period. 
Bonferroni significance level for four comparisons p = 0.013. 
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Table 2. Effect modification by genotypes: associationa of change in average home outdoor PM10 (per 
decrease of 10 µg/m3 between 1991 and 2002) with average annual decline in FEF25–75 (mL/year), by geno-
type status.
Genotype No.
Average annual 
FEF25–75 declineb 95% CI p-Value pintc
 p53 R72P; rs1042522
 GG 2,407 17.37 8.95 to 25.78 < 0.001 0.016(codominant)
 CG 1,637 11.63 2.65 to 20.61 0.011
 CC 282 –4.33 –21.37 to 12.7 0.618
p21 S31R; rs1801270
 CC 3,701 12.72 5.35 to 20.1 0.001 0.115(dominant)
 CA or AAd 625 23.88 9.25 to 38.51 0.001
 CCND1 P242P; rs9344
 GG 1,211 21.33 10.57 to 32.08  < 0.001 0.017(codominant)
 AG 2,140 13.72 5.38 to 22.06 0.001
 AA 975 6.00 –4.54 to 16.54 0.265
CCND1 –7006G>C; rs667515
 GG 1,628 10.39 1.32 to 19.47 0.025 0.006(recessive)
 CG 2,058 11.83 3.24 to 20.42 0.007
 CC 640 28.83 15.6 to 42.07 < 0.001
CCND1 haplotype 1 
(rs667515, rs9344)e
 –/– 3,125 13.67 5.99 to 21.34 < 0.001 0.156(recessive)
 GG/– 1,088 11.1 0.26 to 21.94 0.045
 GG/GG 113 37.77 3.24 to 72.3 0.032
CCND1 haplotype 2 
(rs667515, rs9344)e
 –/– 1,251 20.66 10.07 to 31.24 < 0.001 0.022(codominant)
 GA/– 2,150 13.75 5.34 to 22.15 0.001
 GA/GA 925 6.08 –4.5 to 16.67 0.26
CCND1 haplotype 3 
(rs667515, rs9344)e
 –/– 1,678 10.28 1.22 to 19.35 0.026 0.003(recessive)
 CG/– 2,048 11.92 3.4 to 20.44 0.006
 CG/CG 600 30.9 17.21 to 44.58 < 0.001
CCND1 haplotype 4 
(rs667515, rs9344)e
 –/– 4,239 13.52 6.22 to 20.82 < 0.001 0.434(codominant)
 CA/– 84 –1.4 –39.67 to 36.88 0.943
 CA/CA 3 –11.8 –468.22 to 444.62 0.96
aCovariates were age, age2, sex, height, parental smoking, sine and cosine function of day of examination to control for 
seasonal effects, level of education at SAPALDIA1, change in level of education, Swiss nationality, self-reported occupa-
tional exposure to dust and occupational exposure to fumes at SAPALDIA1 and SAPALDIA2 (yes/no), smoking status at 
SAPALDIA2 (never, former, or current), pack-years up to SAPALDIA1, pack-years between SAPALDIA1 and -2, cigarettes 
per day at SAPALDIA1 and -2, atopy, BMI at SAPALDIA1, change in BMI, interaction between the two BMI variables, 
and baseline PM10 exposure. bPositive estimates indicate attenuation of lung function decline associated with PM10 
decrease. Negative estimates indicate acceleration of lung function decline with PM10 decrease. cp-Value for interaction 
between change in home outdoor exposure of PM10 and genotype parameterized in three different genetic models. The 
pint values presented here represent the most significant (lowest) p-value obtained from the three different genetic mod-
els. Bonferroni significance level for 12 comparisons [three respiratory function tests (FVC, FEV1, FEF25–75) × times four 
association tests], p = 0.00417. dGenotype distribution: p21 CA, n = 594; p21 AA, n = 31. eDiplotype distribution is labeled as 
follows: –/–, none of the specific haplotype present; (rs667515, rs9344)/– (e.g., GG/–), one of the specific haplotypes pres-
ent; (rs667515, rs9344)/(rs667515, rs9344) (e.g., GG/GG), for two of the specific haplotypes present. 
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models. Although p53 and p21 expression 
has been consistently shown to be increased 
upon PM exposure (Bayram et al. 2006; 
Dagher et al. 2006; Jiao et al. 2008; Nyunoya 
et al. 2006; Palozza et al. 2006; Rosas Perez 
et al. 2007; Soberanes et al. 2006; Yao et al. 
2008; Zhang et al. 2007), CCND1 expres-
sion has been reported to be either inhib-
ited (via p21 activation) (Palozza et al. 2006; 
Zhang et al. 2007) or increased [p53-driven 
N-terminal C-Jun kinase (cJUN) activation] 
(Bayram et al. 2006; Dagher et al. 2007; Jiao 
et al. 2008). Such variations in the expres-
sion of cell cycle genes mediate the adaptive 
cellular response to changes in environmen-
tal exposure. They might well be the starting 
point of PM10-induced pathologic changes 
in morphology and in the type and number 
of lung fibroblasts and bronchial epithelial 
cells. Activation of cell proliferation processes 
may help to maintain intact airways even in 
the presence of environmental toxins, as sug-
gested by genetic ablation of p21 in mice, 
which conferred protection against cigarette-
smoke–induced lung inflammation and injury 
(Yao et al. 2008). Aspects of bronchial tissue 
remodeling represent key features of patho-
logic changes in the etiology of most airway 
disorders. However, how proliferation and 
apoptosis relate to airway remodeling in gen-
eral remains poorly understood and is likely 
to be disease specific.
Three of the four polymorphisms investi-
gated here have been studied before, mainly 
in cancer studies, and allelic functional dif-
ferences have been proposed. The functional 
consequence of p53 R72P polymorphism was 
studied in detail. The Arg72-allele (G-allele) 
of p53 is more active at inducing apoptosis 
than is the p53 Pro72-allele. In fact, Pro72 is 
part of a PXXP motif known to be critical in 
binding of a p53-specific inhibitory protein, 
iASPP (inhibitory member of the apoptosis- 
stimulating protein phosphatase family) 
(Bergamaschi et al. 2006). Along the line of 
the proposed functional consequence of this 
genetic variant, meta-analysis results have 
recently shown that the homozygous Pro/Pro 
genotype showed a proproliferative effect and 
was associated with increased gastric cancer 
risk (Zhou et al. 2007). In our association 
study, we observed the most pronounced 
bene fits of ΔPM10 with regard to FEF25–75 
decline in subjects with one or two Arg72-
alleles, which are expected to induce apop-
tosis more potently than the Pro72-allele. In 
contrast, homozygous carriers of the Pro72-
allele did not appear to benefit from the 
improvement in air quality.
The functional studies of the common 
CCND1 polymorphism P242P showed a 
modification of the alternative splicing events 
in exon 4 because the G-to-A substitution 
alters the consensus sequence of the splicing 
donor site (Betticher et al. 1995; Howe and 
Lynas 2001). As recently reported by three 
meta-analyses, the homozygous AA genotype 
was associated with increased risk of various 
types of cancer (Lu et al. 2008; Pabalan et al. 
2008; Tan et al. 2008). The A-allele of the 
CCND1 870G>A (P242P) polymorphism, 
a proposed genetic risk factor for lung can-
cer, was previously associated with impaired 
cell cycle regulation and accumulation of 
DNA damage in the airway (Buch et al. 2005; 
Munnia et al. 2006). In our association analy-
sis, we observed that homo- or heterozygous 
G-allele carriers benefited more from the 
decrease in PM10 exposure than did homozy-
gous A-allele carriers. The association of the 
second CCND1 (–7006G>C) SNP with can-
cer or any other outcome has not been investi-
gated previously. Its functional consequence, if 
any, might be regulatory because it is situated 
upstream of the CCND1 gene. But it is also 
possible that this SNP is in high linkage with 
a yet unknown functional CCND1 variant, 
just as it is also in high LD with the CCND1 
P242P variant.
The polymorphism S31R in the p21 gene 
was shown to be located in the DNA-binding 
zinc finger motif and thus has been thought 
to alter the function of the p21 protein (Lukas 
et al. 1997). However, results of cancer stud-
ies for this SNP have been inconsistent with 
regard to the size and direction of relative risk 
estimates (Choi et al. 2008), and we observed 
no interaction between this SNP and ΔPM10 
on lung function decline.
Thus, the cancer-promoting p53 and 
CCND1 alleles seem to reduce the benefit 
of improved air quality on respiratory func-
tion. Only limited epidemiological data exist 
on the association of p53, p21, or CCND1 
SNPs with respiratory diseases such as asthma, 
emphysema, and chronic obstructive pulmo-
nary disease (COPD). The polymorphisms 
we evaluated in p53 and p21 have previously 
been associated with smoking-related COPD. 
Compared with healthy smokers, the cancer 
risk allele of p53 (Pro72-allele), and the p21 
Arg31-allele were overrepresented in COPD 
patients (Lee et al. 2006). The extrapola-
tion of observed associations with cancer to 
expected associations with lung function is 
not straightforward. The present findings and 
our interpretation of them should be consid-
ered as exploratory in nature and need con-
firmation in independent studies. The relative 
impacts of cell proliferation and apoptosis on 
different cell types in the lung and on respira-
tory function must be further investigated by 
experimental studies.
The strengths of the present study are 
its prospective design, its rather large sam-
ple size, and detailed characterization of the 
study partici pants, as well as the availability 
of individual air pollution exposure history 
since 1990. We were thus able to adjust lung 
function decline for most of the potential con-
founders. Nonetheless, information on some 
relevant confounders such as dietary antioxi-
dant intake and physical activity was collected 
only at follow-up. Lacking data on the degree 
of genetic admixture of the Swiss general popu-
lation is an additional drawback. However, 
we expect little bias due to genetic admix-
ture, because the prevalence of several poly-
morphisms studied in the cohort did not vary 
across the three major Swiss language groups. 
We assessed a very limited number of carefully 
selected candidate polymorphisms; for some of 
the SNPs and haplotypes, and especially for the 
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p21 SNP and CCND1 haplotype 4, statistical 
power to detect effect estimation was very lim-
ited. A more comprehensive assessment of gene 
variants in the apoptosis pathway and genes 
regulating apoptosis in lung tissue needs to be 
addressed in future larger studies. Nevertheless, 
even for the small number of genetic vari-
ants investigated, multiple testing represents a 
limitation in the interpretation of the present 
results. Consistency of the associations across 
genes involved in cell cycle control, as well as 
across various lung function outcomes, dimin-
ishes the likelihood of chance findings, as does 
the strength of the observed pint values.
Finally, participation at follow-up and in 
this present study was not complete, so partici-
pation bias cannot be excluded. However, 
because we observed comparable results in 
all subjects and in never-smokers and in the 
absence of different effects between men and 
women, the lower participation rate in men 
and smokers is not likely to have caused bias.
In conclusion, our results suggest that 
even at low to moderate levels of air pollu-
tion, such as in Switzerland, some but not all 
persons benefit from improved air quality. 
Given the novelty of the finding and the limi-
tations inherent to this study, the results need 
independent confirmation. Future studies 
must address additional issues. First, gene 
variants relevant to cell cycle control must be 
studied more comprehensively. Second, it is of 
interest to know whether this novel candidate 
pathway might determine susceptibility to 
both improvements and declines in air quality.
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